Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec

• DOI: 10.1016/j.ejpn.2024.08.006
• Publication Date: 2024-08-27T09:03:35Z
• Authors: Eduardo F. Tizzano; Susana Quijano-Roy; Laurent Servais; Julie A. Parsons; Sharon Aharoni; Arpita Lakhotia; Richard S. Finkel; Eugenio Mercuri; Janbernd Kirschner; Darryl C. De Vivo; Kayoko Saito; Dheeraj Raju; Kamal Benguerba; Omar Dabbous; Nayla Mumneh; Sandra P. Reyna; Eric Faulkner
• Keywords: Progressive muscular atrophy

We describe outcomes following onasemnogene abeparvovec monotherapy for patients with ≥four survival motor neuron 2 (SMN2) gene copies in RESTORE, a noninterventional spinal muscular atrophy patient registry.We evaluated baseline characteristics, motor milestone achievement, post-treatment motor function, use of ventilatory/nutritional support, and adverse events as of December 22, 2022.At data cutoff, 19 patients in RESTORE had ≥four SMN2 copies and were treated with onasemnogene abeparvovec monotherapy (n=12 [63.2%] four copies; n=7 [36.8%] >four copies). All patients were identified by newborn screening and were reported as asymptomatic at diagnosis. Median age at onasemnogene abeparvovec administration was 3.0 months. Median time from treatment to last recorded visit was 15.4 months, with a range of post-treatment follow-up of 0.03-39.4 months. All 12 children who were assessed for motor development achieved new milestones, including standing alone (n=2) and walking alone (n=5). Five children reported one or more treatment-emergent adverse events (one Grade 3 or greater). No deaths or use of ventilatory/nutritional support were reported.Real-world findings from the RESTORE registry indicate that patients with ≥four SMN2 gene copies treated with onasemnogene abeparvovec monotherapy demonstrated improvements in motor function. Adverse events experienced by these patients were consistent with previously reported findings.